BRCA2 and breast cancer: Mutations detected included OncoKB Level 1 alterations (defined as predictive biomarkers of response to an FDA-approved drug) such as BRCA2 mutations, which are predictive of response olaparib (a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor) in prostate cancer [33], and PIK3CA mutations, which are predictive of response to alpelisib (a selective PI3 kinase inhibitor) in breast cancer [34] (Fig. 4c).